Indian Biogenerics: An Evolving Industry - Indian biogenerics could form a major piece of the global biotherapeutics market in the future. - BioPharm International

ADVERTISEMENT

Indian Biogenerics: An Evolving Industry
Indian biogenerics could form a major piece of the global biotherapeutics market in the future.


BioPharm International
Volume 21, Issue 2

The bioequivalence issue in the US is awaiting legislation that would amend Sec. 262 of the Public Health Service Act. Major healthcare legislation is unlikely in 2008, an election year, and passage of a standalone biogenerics bill is also unlikely, given the opposition by the Pharmaceutical Research and Manufacturers of America and other lobbying groups for innovator biotech companies.7 In late 2005, the EMEA gave final approval to basic guidelines for Similar Biological Medicinal Products.8 Since then, it has approved two growth hormone biosimilars, Sandoz's Omnitrope and Biopart-ners' Valtropin, in early 2006, as well as Sandoz's EPO biosimilar in August 2007.

OUTLOOK

The opening up of the European biosimilars market marks the end of the beginning of the biogenerics industry. Products made by India's biogenerics makers or their Western licensees will appear in European pharmacies as soon as their abbreviated clinical research requirements and EMEA reviews are completed successfully. Biogenerics will ultimately take, and keep, a significant chunk of the global biotherapeutics market, as biotherapeutics themselves take a larger portion of the global pharmaceuticals market.

But in the near term, the biosimilars market isn't as appealing as it might seem. The lack of US legislative action so far, the unlikelihood of action any time soon, and the evident opposition to such legislation, reduces the available market. And it is far from clear that when such legislation is enacted, it will include terms that make the follow-on biologics market attractive for India's generics makers.

Even in the European biosimilars market there is room for skepticism. Two of the first three approved biosimilars are competing against each other, and the more popular one of the two, Sandoz's Omnitrope, has so far captured less than 1% of the European HGH market, despite being priced up to 25% lower than the drug it was made to resemble, Pfizer's Genotropin.9

For Indian companies, a smaller piece of the pie may still be enough to justify their efforts. But some may elect to license development and marketing in Western markets to Western partners—as Biocon already has done for its G-CSF biogeneric—in advance of approval. And as Biocon's evolution also has shown, biogenerics may represent only a passing phase for some Indian biotech companies, who prefer to focus their R&D efforts on the creation of new and patentable biologics. Indeed, the same national pride that makes Indians want to excel at IT and biotechnology seems to make some of them anxious to outgrow the country's "cheap generics" reputation. Dr. Swati A. Piramal, director of an R&D center for Nicholas Piramal in Mumbai, was quoted not long ago as saying, "Indian companies are no longer going to be just copycats. We want to take our rightful place at the head table with the developed nations."10

Eric Langer is president and managing partner at BioPlan Associates, Inc., Rockville, MD, 301.921.9074.
.

REFERENCES

1. Indian biotech industry clocks $2 billion. BioSpectrum: 2007 July 21.

2. Biopectrum 2005. Biospectrum ABLE Industry Survey. 2005 June 3,6,24.

3. Dabas M. Interview with Kapil Sibal. Biotech News, Dept of Biotechnology. Accessed 2007 Nov 24. http://www.biotechnews.in/readeditor_1lt.html.

4. Curing India: Biocon Takes on Cancer and Diabetes. Fortune: 2006 Oct 2.

5. Dr. Reddy's scripts plan for biogenerics thrust. http://Rediff.com/. 2001 Jul 24. Acc-essed 2007 Nov 24. http://im.rediff.com/money/2001/jul/24reddy.htm.

6. Kumar A. Biogeneric Manufacturing in India. In: Langer E, editor. Advances in Biopharmaceutical Technology in India. Gaithersburg, MD: Bioplan; Feb 2008.

7. Perrone M. Generic Biotech Agreement Proves Elusive. AP 2007 Sept 20. Accessed 2007 Nov 24. http://biz.yahoo.com/ap/070920/generic_biotech_congress.html?.v=1.

8. European Commission (Enterprise Directorate General). EMEA Guideilne on Similar Biological Medicinal Products. Brussels, Belgium: 2005 Oct.

9. Biosimilars: How Strong a Market? Accessed 2007 Nov 24. http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_41382706_82367735,00.html.

10. India: Bigger Pharma. Businessweek: 2005 Apr 18.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here